REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and PlaceboGlobeNewsWire • 06/30/22
Amarin Receives Positive Recommendation from United Kingdom's (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA® (icosapent ethyl)GlobeNewsWire • 06/10/22
Amarin Corporation plc's (AMRN) CEO Karim Mikhail on 2022 Jefferies Global Healthcare Conference (Transcript)Seeking Alpha • 06/08/22
Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. BusinessGlobeNewsWire • 06/06/22
Amarin Corporation Plc (AMRN) CEO Karim Mikhail on H.C. Wainwright Global Investment Conference (Transcript)Seeking Alpha • 05/25/22
Research Presented at the American Heart Association's Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated CostsGlobeNewsWire • 05/16/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amarin Corporation plc - AMRNNewsfile Corp • 05/09/22
Amarin Corporation plc (AMRN) CEO Karim Mikhail on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/04/22
Amarin Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 05/04/22
New Analysis Reveals Icosapent Ethyl Significantly Reduces Risk of Major Cardiovascular Events in Patients with Prior Myocardial Infarction (Heart Attack)GlobeNewsWire • 05/03/22
Amarin Partner HLS Therapeutics Completes Reimbursement Negotiations with Pan-Canadian Pharmaceutical Alliance (pCPA) for VASCEPA® (icosapent ethyl)GlobeNewsWire • 04/26/22